The 2008 San Antonio Breast Cancer Symposium, held December 10–14, provided greater insight into the potential of molecular assays, presented updated adjuvant aromatase inhibitor trials, and offered new data regarding the use of targeted agents in neoadjuvant and metastatic disease settings. Several key presentations are summarized below. For more information, readers are encouraged to review the conference website.
Oncotype DX Assay
In the TransATAC study [Abstract 53], investigators assessed the ability of the Oncotype DX assay to predict risk for distant disease recurrence in postmenopausal primary breast cancer patients treated with anastrozole (Arimidex) or tamoxifen. Although the assay’s recurrence score (RS) has been validated to estim…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)